Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Fayers
Madeleine King

Showing results (161-170 of 176) with videos related to

Pageof 18
Sort By:
The Oncologist|June 10, 2017
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit StudyFelicia T Roncolato, Florence Joly, Rachel O'Connell, et al.
The Lancet. Oncology|September 25, 2010
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trialPeter Gimsing, Kristina Carlson, Ingemar Turesson, et al.
Targeted Oncology|November 9, 2020
Developing Symptom Lists for People with Cancer Treated with Targeted TherapiesSamantha C Sodergren, Sally J Wheelwright, Deborah Fitzsimmons, et al.
Pediatric Blood & Cancer|March 13, 2026
Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective StudyBenjamin J Lerman, Madeleine King, Rajen Mody, et al.
Cancers|November 27, 2021
Providing Psychological Support to Parents of Childhood Cancer Survivors: '<i>Cascade</i>' Intervention Trial Results and Lessons for the FutureClaire E Wakefield, Ursula M Sansom-Daly, Brittany C McGill, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 1, 2011
Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 dataFrancesca Martinelli, Chantal Quinten, John T Maringwa, et al.
Blood|May 8, 2010
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myelomaAnders Waage, Peter Gimsing, Peter Fayers, et al.
Journal of Clinical Epidemiology|November 9, 2021
A systematic survey identified methodological issues in studies estimating anchor-based minimal important differences in patient-reported outcomesYuting Wang, Tahira Devji, Anila Qasim, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 2, 2010
Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trialsJohn T Maringwa, Chantal Quinten, Madeleine King, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 23, 2021
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancerPaul A Cohen, Penelope M Webb, Madeleine King, et al.
Pageof 18

Showing results (161-170 of 176) with videos related to

Sort By:
Pageof 18
The Oncologist|June 10, 2017
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit StudyFelicia T Roncolato, Florence Joly, Rachel O'Connell, et al.
The Lancet. Oncology|September 25, 2010
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trialPeter Gimsing, Kristina Carlson, Ingemar Turesson, et al.
Targeted Oncology|November 9, 2020
Developing Symptom Lists for People with Cancer Treated with Targeted TherapiesSamantha C Sodergren, Sally J Wheelwright, Deborah Fitzsimmons, et al.
Pediatric Blood & Cancer|March 13, 2026
Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective StudyBenjamin J Lerman, Madeleine King, Rajen Mody, et al.
Cancers|November 27, 2021
Providing Psychological Support to Parents of Childhood Cancer Survivors: '<i>Cascade</i>' Intervention Trial Results and Lessons for the FutureClaire E Wakefield, Ursula M Sansom-Daly, Brittany C McGill, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 1, 2011
Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 dataFrancesca Martinelli, Chantal Quinten, John T Maringwa, et al.
Blood|May 8, 2010
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myelomaAnders Waage, Peter Gimsing, Peter Fayers, et al.
Journal of Clinical Epidemiology|November 9, 2021
A systematic survey identified methodological issues in studies estimating anchor-based minimal important differences in patient-reported outcomesYuting Wang, Tahira Devji, Anila Qasim, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 2, 2010
Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trialsJohn T Maringwa, Chantal Quinten, Madeleine King, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 23, 2021
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancerPaul A Cohen, Penelope M Webb, Madeleine King, et al.
Pageof 18